Investigative Ophthalmology & Visual Science Cover Image for Volume 59, Issue 9
July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Comparison of efficacy and safety of accelerated trans-epithelial crosslinking for keratoconus patients with corneas thicker and thinner than 380µm
Author Affiliations & Notes
  • Kentaro Abe
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Takashi Miyai
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Tetsuya Toyono
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Wei Aixinjueluo
    Department of Ophthalmology, Tokyo Teishin Hospital, Tokyo, Japan
  • Tatsuya Inoue
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Shotaro Asano
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Hitoha Ishii
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Junko Yoshida
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Rika Shirakawa
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Tomohiko Usui
    Department of Ophthalmology, The University of Tokyo, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Kentaro Abe, None; Takashi Miyai, None; Tetsuya Toyono, None; Wei Aixinjueluo, None; Tatsuya Inoue, None; Shotaro Asano, None; Hitoha Ishii, None; Junko Yoshida, None; Rika Shirakawa, None; Tomohiko Usui, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4382. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kentaro Abe, Takashi Miyai, Tetsuya Toyono, Wei Aixinjueluo, Tatsuya Inoue, Shotaro Asano, Hitoha Ishii, Junko Yoshida, Rika Shirakawa, Tomohiko Usui; Comparison of efficacy and safety of accelerated trans-epithelial crosslinking for keratoconus patients with corneas thicker and thinner than 380µm. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4382.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal cross-linking has been established as an effective therapy to prevent progression of keratoconus. Accelerated trans-epithelial cross-linking (ATE-CXL) has been developed with the merit that it is a shorter time procedure without corneal epithelial removal and thinner cornea (≧380μm) can be the indication. In the present study, we compared efficacy and safety of ATE-CXL for keratoconus between thinner and thicker than 380μm.

Methods : Thirty-four eyes of 27 patients, who underwent ATE-CXL (30mW/cm2, 3min) with completion of 24 months follow-up, were enrolled. The eyes were divided into two groups: Group1,10 eyes of 8 patients with thinnest cornea thickness (TCT) <380um; Group 2, 24eyes of 19 patients with TCT≧380um. Hypotonic solution was administrated to Group1 until corneal thickness increased more than 380um at the intraoperative measurements before UV-A irradiation.
We measured uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), maximum and average keratometric values (K-max, Ave-K), central corneal thickness (CCT), TCT by anterior segment OCT and corneal endothelial cell density (ECD) by specular microscopy. The changes from baseline to 24 months after surgery between the two groups were compared. Linear mixed model was used for statistic. P<0.05 was set as statistical significance.

Results : K-max at baseline and 24 months in Group 1 was 68.9±8.1 D, 61.1±6.1 D. That in Group 2 was 54.5±6.5, 54.8±7.5. The changes of K-max and Ave-K from baseline to 24 months in Group1 (ΔK-max: -7.8±7.7 D, ΔAve-K: -4.3±6.1 D) were significantly smaller than those in Group 2 (ΔK-max: 0.2±3.0 D, ΔAve-K: 0.6±2.7 D) (p<0.001 and p=0.01, respectively), whereas the changes from baseline and 24 months after surgery in UCVA, BCVA, CCT, TCT and ECD did not show statistical differences between the groups.

Conclusions : ATE-CXL is not only an effective and safe treatment for keratoconus patients with corneal thickness more than 380µm but also for corneas thinner than 380µm. The effect of reducing keratometric values was stronger for the group of thinner corneas.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×